- Home
- / Cellectis
Cellectis
Stock Price
€1.7
2024-10-29
Market Capitalization
€175.4 M
2024-10-29
Revenue
$72.9 M
FY, 2025
Cellectis Summary
Company Summary
- Overview
- Cellectis is a clinical-stage biopharmaceutical company that develops cell and gene therapies. It offers a gene-editing platform that develops a new generation of cancer immunotherapies based on engineered allogeneic T-cells.
- Type
- Public
- Status
- Active
- Founded
- 1999
- HQ
- Paris, FR | view all locations
- Website
- https://www.cellectis.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Philippe Duchateau, Chief Scientific Officer
Steve Doares, Senior Vice President, US Manufacturing and Site Head
Mark Frattini, Chief Medical Officer
LocationsView all
3 locations detected
Paris, IDF HQ
France
8 Rue de la Croix Jarry
New York, NY
United States
430 E 29th Street
Raleigh, NC
United States
2500 Sumner Boulevard
Cellectis Financials
Summary Financials
- Revenue (Q1, 2026)
- $5.8M
- Gross profit (Q1, 2026)
- $7.6M
- Net income (Q1, 2026)
- ($17.8M)
- Cash (Q1, 2026)
- $34.8M
- EBIT (Q1, 2026)
- ($25.2M)
- Enterprise value
- $249.1M